At National Taiwan University's Graduate Institute of Microbiology, researchers refined a delicate balance that could reshape how scientists study the gut's role in cancer — and how they treat the laboratory mice that make such discoveries possible. By lowering antibiotic doses in what's known as a pseudo-germ-free mouse model, Prof. Wei-Kai Wu's team achieved something rarely easy in science: they made the experiment both more humane and more reliable.
The challenge they tackled is increasingly urgent. Pancreatic cancer remains one of the most difficult cancers to treat, and emerging evidence suggests that gut microbes play a surprising role in how tumors grow and respond to therapy. To study this connection, researchers have long used pseudo-germ-free mice — animals whose gut bacteria are drastically reduced through antibiotics. But the standard approach comes with a dark trade-off: the high antibiotic doses required cause severe side effects in the mice themselves, including reduced eating and drinking, dramatic weight loss, and sometimes death. The welfare cost has made the model both unreliable and ethically troubling.
Wu's team changed that by systematically testing lower-dose antibiotic regimens. Their results, published in the Journal of Advanced Research, showed something encouraging: reduced doses could strongly decrease gut bacterial levels while causing significantly less body weight loss and better survival rates. The team also tested whether adding sucrose to improve the taste might help, but found that sweetening the antibiotic cocktail didn't provide clear benefits and may have even encouraged residual bacteria to persist — an unexpected finding that suggests simpler is sometimes better.
With this refined model established, the researchers turned their attention to pancreatic ductal adenocarcinoma, a major form of pancreatic cancer. Mice treated with the lower-dose antibiotic regimens developed noticeably smaller tumors than untreated mice. The same pattern held in fully germ-free mice, reinforcing an important insight: the presence of certain gut microbes appears to actively support tumor growth.
But the most striking discovery came when they combined antibiotic treatment with gemcitabine, a chemotherapy drug widely used for pancreatic cancer. The combination was more powerful than either treatment alone. When researchers analyzed protein patterns in tumor tissue from antibiotic-treated mice, they found shifts in cancer-related pathways: reduced tumor-supporting metabolism and inflammation, alongside increased pathways linked to cancer cell stress and death. The gut, it seemed, was whispering instructions to the tumor.
Ming-Shiang Wu, distinguished professor of internal medicine at National Taiwan University, frames the implications clearly: these findings suggest that modulating the microbiome might become a useful strategy to support future cancer treatment. For now, the refined pseudo-germ-free model offers researchers a safer, more reproducible tool for investigating how gut microbes influence disease progression across many conditions, not just cancer. And for the mice themselves, it means science that harms less while discovering more — a small but meaningful step toward more thoughtful research.